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Systematic review of randomized
controlled trials in the treatment of dry eye
disease in Sjogren syndrome
Kendrick Co Shih1†, Christie Nicole Lun2†, Vishal Jhanji3,4, Bernard Yu-Hor Thong5 and Louis Tong6,7,8,9*
Abstract: Primary Sjögren’s syndrome is an autoimmune disease characterized by dry eye and dry mouth. We
systematically reviewed all the randomized controlled clinical trials published in the last 15 years that included ocular
outcomes. We found 22 trials involving 9 topical, 10 oral, 2 intravenous and 1 subcutaneous modalities of treatment.
Fluoromethalone eye drops over 8 weeks were more effective than topical cyclosporine in the treatment of dry
eye symptoms and signs; similarly, indomethacin eye drops over 1 month were more efficacious than diclofenac eye
drops. Oral pilocarpine 5 mg twice daily over 3 months was superior to use of lubricants or punctal plugs for treating dry
eye, but 5% of participants had gastrointestinal adverse effects from pilocarpine, though none discontinued treatment. In
contrast, etanercept, a TNF-alpha blocking antibody, administered as subcutaneous injections twice weekly, did not
improve dry eye significantly compared to placebo injections. In conclusion, topical corticosteroids have been shown
to be effective in dry eye associated with Sjögren’s syndrome. As some topical non-steroidal anti-inflammatory drugs
may be more effective than others, these should be further evaluated. Systemic secretagogues like pilocarpine have a
role in Sjögren’s syndrome but the adverse effects may limit their clinical use. It is disappointing that systemic cytokine
therapy did not produce encouraging ocular outcomes but participants should have assessment of cytokine levels in
such trials, as those with higher baseline cytokine levels may respond better.
(229 words)
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Background
Sjögren’s syndrome (SS) is a gradual and progressive
autoimmune disease that primarily targets the exocrine
glands. It is estimated that the worldwide incidence of
Sjögren’s is 7 per 100,000 people, with the highest inci-
dence rates in Europe and Asia, reaching up to 43 per
100,000 people [1]. In view of such statistics, there is a
relative lack of evidence-based treatment on Sjögren-re-
lated keratoconjunctivitis sicca (KCS).
SS is characterized by the replacement of functional
epithelium with lymphocytic infiltrates, leading to gradual
gland destruction and impaired exocrine secretions.
Impaired glandular excretion results in sicca symptoms
such as oral and ocular dryness. Dry eye from SS is more
severe than idiopathic dry eye, so treatment modalities that
work in idiopathic dry eye may or may not be effective in
SS. There are several reviews and meta-analyses concern-
ing the treatment of dry eye in primary SS, such as rituxi-
mab and hydroxychloroquine, but evidence for their
therapeutic efficacies is weak. [2–4] In order to address
these issues, a systematic review is conducted to summarize
and analyze the current evidence for the management of
SS-related dry eye, focusing on the efficacy and safety of
various topical and systemic treatments, published in the
last 15 years, in randomized controlled trials (RCT).
Methods
We searched the Entrez Pubmed database on the 18th
of April, 2017 with the key words “Sjögren’s Syndrome”,
and the MESH keywords “therapy” and “controlled trial”
and found one hundred and 38 entries.
These papers were then manually curated (by KS, CL,
LT) to include only those that reported ocular efficacy
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outcomes (symptoms and signs of dry eye). Among the in-
cluded articles, only papers published within the past 15
years were eligible, and only papers that recruited patients
with primary SS were included. Studies that did not specify
the patients to be diagnosed with rheumatoid arthritis, sys-
temic lupus erythematosis or another named autoimmune
disease were included as we assumed those participants
had primary SS. We only included articles with full text
available in English. We allowed control groups in these
studies to use either placebo or standard therapy. With
these criteria, we narrowed our results to 20 entries in
total. The search strategy was further clarified to include
alternate spellings of Sjogren’s syndrome, such as “Sjogren”,
“Sjogren Syndrome” and “Sjogren’s”. Other MESH key-
words such as “therapy” and “management” were also
tested, but did not yield any further results. The references
of the curated results were further checked for relevant
articles.
Topical or ophthalmic interventions
We found nine reports on topical interventions and all of
them were from single-centered studies; two of these
assessed steroidal eye drops: fluoromethalone (FML) and
clobetasone. These seven studies did not have large sample
sizes: the two studies on steroidal eye drops [5, 6] and the
study on punctal plugs [7] recruited only 40 patients each,
with the other studies having even smaller samples. Only
two of these studies [8] [9] were double-masked. All the
studies showed some benefit in efficacy outcomes of dry
eye symptoms and signs except tacrolimus eye drops,
which only improved clinical signs. Topical steroids,
autologous serum eye drops, topical non-steroidal anti-
inflammatory drugs (NSAIDs), diquafosol sodium eye drops,
punctual plugs, and wearing bandage contact lens (BCL)
were associated with improvement in both symptoms and
signs. All studies were parallel group RCTs, except the study
on autologous serum eye drops, which had a crossover de-
sign. Table 1 summarizes the key findings from these studies.
Both the RCTs on the use of steroidal eye drops showed
an improvement in both signs and symptoms of dry eye
disease, ie. corneal fluorescein staining (CFS) and Ocular
Surface Disease Index (OSDI) symptom score. [5, 6] The
study on clobetasone lasted only thirty days, and the com-
parator was artificial tears. In contrast, the comparator for
FML eye drops was topical cyclosporine. In studies recruit-
ing SS patients with more severe dry eye, it may not be
ethical to use artificial tear as a comparator, since partici-
pants would likely need some form of immunosuppressive
treatment to meet standard of care. Both studies similarly
recruited SS patients with moderate to severe dry eyes.
A newer T-cell immunosuppressant, tacrolimus, reported
to be a hundred times more potent than cyclosporine in
in-vitro studies, has been evaluated in a RCT. [10] Over a
period of 3 months, instillation of tacrolimus 0.03% eye
drops twice daily showed improvement in conjunctival and
CFS (P = 0.008) but not Schirmer I (P = 0.014), compared
to almond oil eye drops. [8] Unfortunately measurement of
dry eye symptoms was not designated as a trial outcome.
In the RCT, 11/ 14 (78.6%) of patients randomized to ta-
crolimus complained of burning sensation. [8] All patients
said that burning lasted for 30 minutes after drop instilla-
tion, but none stopped the medication. This modality of
treatment may be promising if patients can tolerate the as-
sociated burning sensation.
Despite the fact that NSAIDs eye drops have been re-
ported to cause corneal melting [11], scientific evidence
supports the use of NSAIDs in dry eye. Firstly, NSAIDs
reduce pro-inflammatory eicosanoids in the arachidonic
acid pathway. Secondly, the NSAID indomethacin has
been shown to reduce chemokines and infiltration of lym-
phocytes into inflamed tissue. There should be caution in
the use of some NSAIDs, diclofenac but not indomethacin
reduced corneal sensitivity in normal people. [12] Unfor-
tunately, we did not find a RCT that compared NSAIDs
with a non-NSAID comparator. One RCT compared in-
stillation of 0.1% indomethacin with 0.1% diclofenac eye
drops 3 times daily over 30 days.[13]Both treatments pro-
duced an improvement in dry eye symptoms compared to
their baseline levels (P < 0.01 for indomethacin; P < 0.05
for diclofenac). At 30 days, both symptoms and signs (tear
breakup time [TBUT] and CFS) were not statistically dif-
ferent between the two types of NSAIDs. At the same time
point, corneal sensitivity significantly decreased compared
to baseline (P < 0.04 for indomethacin; P < 0.04 for
diclofenac).
This RCT allowed liberal use of tear substitutes but the
actual frequency of use of each type of eye drops was not
reported. The observed improvement in dry eye could be
partly due to the concomitant use of tear substitutes. In
addition, the scoring system for ocular discomfort was not
validated. The study did not mention the incidence of
stinging or irritation, which had been encountered after
the use of topical NSAIDs. Reassuringly, there were no
cases of keratolysis. [13]
Autologous serum is a novel form of treatment for
severe dry eye. [14] It consists of various plasma proteins
that may have a wound healing or immunosuppressive
effect in recalcitrant cases of dry eye. [15] The only RCT
in autologous serum in SS employed a parallel group
crossover design. [16] The investigators concluded that a
bottle of autologous serum (50%) daily was superior to
conventional treatment for ocular surface dye staining
(P < 0.02), and subjective comfort (P < 0.01) levels (face
scale) over a period of 6 months. [16] The major problem
with crossover studies in dry eye is that the adequacy of
the washout period in between the two treatments is pos-
sibly insufficient, as the residual effect of interventions like
autologous serum after cessation is unknown. It is unusual
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to use a face scale in dry eye studies instead of a validated
symptom questionnaire. The authors also reported diffi-
culties concerning the logistics of serum extraction and
processing, suggesting that implementation in clinical
practice will be challenging.
Diquafosol sodium (DQS) is known to increase tear
fluid and mucin production on the ocular surface by
acting as an agonism of the P2Y2 purinogenic receptor.
[17] In this RCT, 17 study subjects were each instilled
with one drop of 3% DQS on one randomly chosen eye
and compared ocular efficacy outcomes with its baseline.
After 15 min, there is a significant improvement in dry
eye symptoms (P < 0.001) and central lower tear menis-
cus radius (TMR) curvature measurement (P < 0.0001).
[18] Although this study shows an increase in aqueous
tear volume after instillation of DQS, it cannot reflect
any long-term effect DQS potentially has on the treat-
ment of dry eyes.
Lacrimal punctal occlusion is a major form of treat-
ment in dry eye, especially in patients with aqueous tear
deficiency. However, there is a potential drawback
because retention of tears may be associated with accu-
mulation of pro-inflammatory cytokines in the tear and
ocular surface. Both RCTs on the use of punctal plugs
were reported to be beneficial compared to conventional
treatment. [7, 9] In one RCT, thermosensitive punctal
plugs were inserted in the superior and inferior puncta
of each eye and showed statistical improvement in terms
of OSDI (P < 0.001), CFS (P < 0.001) Schirmer I (P <
0.001) and TBUT (P < 0.001). [7] Unfortunately the
study did not report the levels of tear cytokines. The
other RCT is a uniocular study that inserted silicone
punctal plugs in both the inferior and superior puncta
on one eye only in each subjects with comparison to
their fellow eye. There is statistical significance in Rose
Bengal (P < 0.02) and dry eye symptoms (P < 0.01). [9]
However, the sample size is too small and study duration
is too short for the assessment of long-term benefits.
Application of BCL is commonly used in clinics to pro-
mote wound healing, especially in cases of persistent cor-
neal epithelial defects. [19] The use of contact lens in
severe dry eye is usually restricted to scleral or PROSE type
hard lenses as opposed to soft BCL. The use of soft diam-
eter BCL is associated with corneal hypoxia and even in-
fective keratitis. Therefore, a RCT is appropriate to
determine if BCLs are beneficial in SS. However, it is worth
noting that Li et al. compared BCL against use of autolo-
gous serum eye drops instead of artificial tears. [20] Even
then, BCL was found to be superior to autologous serum in
terms of dry eye symptoms, ie. OSDI (P = 0.014) and clin-
ical sign, ie. CFS (P < 0.01). [20] Schirmer I results were not
changed between or within the groups after 6 weeks.
The BCL used in the RCT was made of silicon-hydrogel
balafilcon A with 36% water content. [20] For obvious
reasons, there was no participant masking. It was not clear
if there was investigator masking. Interestingly, the partici-
pants had not been reported to use concomitant prophy-
lactic antibiotic eye drops in this study. The investigators
monitored best corrected visual acuity (BCVA) and
showed significant improvement in the BCL group (P =
0.003), but not the placebo group. [20] No cases of kera-
titis were reported. However, the study was only 6 weeks
in duration and safety of the intervention arms over a lon-
ger period remains uncertain.
Systemic interventions
Efficacy
We found 13 articles on systemic interventions for dry
eye in SS. All evaluated oral agents except etanercept
and rituximab, which were administered by subcutane-
ous and intravenous injection respectively. Two [21, 22]
out of 13 studies have large sample sizes (above a hun-
dred and fifty patients), and four of them are multi-
centered RCTs. [21, 23] Studies with oral pilocarpine
and doxycycline recruited only female participants. [24,
25] All studies were double-masked except for two. [25,
26] In summary, oral pilocarpine, cevimeline, lactoferrin,
a traditional Chinese medicine (TCM) herb and linoleic
acid/ gamma linoleic acid (5/13 systemic modalities)
were found to be more effective than placebo or artificial
tear in the treatment of dry eye. [22, 23, 25–28] Table 2
summarizes the key findings from these studies.
Pilocarpine is a muscarinic agonist that stimulates secre-
tion of saliva, aqueous tear from lacrimal glands, conjunc-
tival epithelium and mucin from goblet cells. [29]
Administration of 5 mg of pilocarpine twice daily, for
12 weeks improved dry eye symptoms and Rose Bengal dye
staining compared to the combination of artificial tears and
inferior puncta occlusion. [25] The investigators did not clar-
ify whether other medications such as systemic immunosup-
pressant were used or if a washout period was implemented.
Cevimeline is a parasympathomimetic drug that acts
like pilocarpine, except that it has a longer serum half-
life. [30] Two RCTs [22, 28] showed that treatment with
cevimeline compared to placebo improved symptoms
(Visual analog scale) and signs (Schirmer I) of dry eye.
Oral cevimeline (15 mg) thrice daily is superior to pla-
cebo in terms of symptoms and signs of dry eye. There
is some controversy as to whether a higher dosage of
30 mg thrice daily would provide further benefit. Al-
though Petrone et al. is a randomized study, participants
who received 15 mg had more severe dry eyes than
those with 30 mg. Due to the differential severity at
baseline, the interpretation of results is more difficult. In
these studies the rationale for the dosages used was not
explained, and especially, why doses lower than 15 mg
were not considered.
Shih et al. Journal of Inflammation  (2017) 14:26 Page 7 of 11
Elevated levels of plasma matrix metalloproteinase
(MMP) have been reported in primary SS patients, [31]
suggesting that these molecules could be therapeutic tar-
gets. Doxycycline is known for its bacteriostatic proper-
ties, but at low doses, it suppresses MMPs. [32] Oral
doxycycline 20 mg twice daily for 10 weeks was not
found to be better than placebo in terms of relieving dry
eye symptoms. [24] Unfortunately the signs of dry eye
were not evaluated.
Tumor necrosis factor alpha (TNF-α) is an immune
mediator that has been targeted in the treatment of
inflammatory diseases. However, one such therapy,
subcutaneous etanercept twice weekly for 3 months, did
not improve symptoms and signs (Schirmer I, lissamine
green staining) of dry eye compared to placebo. [33] It is
possible that the drug was unable to reach target tissues or
a larger dose may be needed.
Dehydroepiandrosterone (DHEA) is a steroid hormone
that is currently under study for its role in autoimmune
diseases. Patients with primary SS have been found to
have dysfunctional hypothalamic-pituitary-adrenal axes.
[34, 35] DHEA could be converted into testosterone or
estrogen intra-cellularly and replenish the suppressed
hormonal levels in primary SS patients, thus improving
sicca symptoms. [34, 35] However, daily administration
of 200 mg DHEA for 6 months did not improve dry eye
symptoms and signs (Schirmer I and lissamine green
staining) compared to placebo. [36] Unfortunately
plasma DHEA levels were not measured on study sub-
jects, and patients with lower DHEA may potentially
benefit more.
Lactoferrin is an interesting modality of treatment.
First, lactoferrin is a major tear protein whose concen-
tration is found decreased in dry eye. [37] Second, lacto-
ferrin could modulate oxidative stress and regulate
microbes. [38] Dogru et al. conducted a 1-month 2-
group crossover RCT evaluating oral lactoferrin capsules
(270 mg/day) with a small sample size. [26] Lactoferrin
improved corneal sensitivity (P < 0.01), TBUT (P < 0.01)
and tear film lipid layer thickness (P < 0.01) when com-
pared to placebo. [26] Unfortunately, the beneficial effect
was not sustainable a month after cessation of lactofer-
rin. The type of lactoferrin (recombinant or bovine) and
bioavailability after oral intake were not reported, and
tear lactoferrin levels were not determined. [26] Clini-
cians should be cautious about applying such results to
clinical practice due to a lack of mechanistic investiga-
tions in relation to the results from this study. It remains
to be seen whether oral administration of lactoferrin has
an indirect beneficial effect on the ocular surface through
modulation of gut microflora, or whether it exerts effects
directly on the tear film.
Hydroxychloroquine (HCQ) is a disease modifying
anti-rheumatic drug. It can antagonize toll-like receptors
9 and 7 to inhibit the production of inflammatory
markers such as IL-6, known to be overexpressed in SS.
[39] In a 12-week RCT on primary SS patients that com-
pared the effect of 300 mg/day oral HCQ and placebo.
[40] HCQ did not improve symptoms (OSDI) and signs
(TBUT, Schirmer I and CFS) of dry eye, compared to
placebo. [40] A longer study (24-week) with a higher
dose of HCQ (400 mg/day) still did not improve symp-
toms (Sicca Symptoms Inventory) and signs (TBUT and
Schirmer I). [21] However, in these studies, it was un-
clear if other immunosuppressants were stopped prior
to the use of HCQ.
Rituximab is a monoclonal antibody that targets hu-
man CD20 on B-cells. Recently, it has been extensively
researched for its potential therapeutic use on treating
symptoms and signs of Sjogren’s syndrome as a target
therapy. [41] Two large multi-centered, double blind,
RCTs (TEARS, TRACTISS) evaluated the efficacy of ad-
ministrating 1 g of Rituximab intravenously against pla-
cebo on patients with primary SS. Ocular symptoms and
signs (only Schirmer I) were measured in both studies as
secondary outcomes. There was no statistical signifi-
cance on the endpoints of ocular dryness and Schirmer I
in both studies. [42–44] They both concluded insuffi-
cient evidence to support the use of Rituximab in most
patients with Sjogren’s syndrome. TEARS recruited sub-
jects who were newly diagnosed with primary SS, so low
disease activity at baseline was a potential a limiting
factor for statistically insignificant results. [44]
Various modalities of TCM have been evaluated in dry
eye based on the restoration of ‘yin deficiency’ in specific
organs. [23] SS-related sicca symptoms and Schirmer I
were evaluated after ingestion of a mixed Chinese herb:
ShengJunRunZaoYangXue granules 200 g/day for 6 weeks.
[23] These outcomes were improved compared to placebo.
Apart from Schirmer I, no other clinical tests of dry eye
had been performed. In the study, patients were permitted
to continue with other systemic medications such as oral
prednisolone, HCQ and other immunosuppressive drugs
provided they had been commenced at least 3 months
prior to randomization. Nevertheless, the number of such
patients included in the study was not reported. Limited
knowledge on the molecular mechanisms and targets
limits wider adoption of such treatments in routine clinics.
Gamma-linolenic acid (GLA) is an essential omega-6
fatty acid shown to have anti-inflammatory effects in
chronic inflammatory diseases. [45] GLA is metabolized
into dihomo-γ-linolenic acid (DGLA), an immediate pre-
cursor of prostaglandin-E (PGE), an eicosanoid known
for its inflammation modulating abilities. [46] A study
has found an inverse association between GLA levels
and levels of anti-SSA/anti-Ro antibodies. [47] Aragona
et al. conducted a double-masked RCT using oral con-
sumption of omega-6 essential fatty acids (127 mg)
Shih et al. Journal of Inflammation  (2017) 14:26 Page 8 of 11
compared to placebo for 1 month. [27] Symptoms of dry
eye and CFS were improved at the end of treatment and
15 days after stopping treatment. Interestingly, tear PGE
levels (P < 0.01) increased compared to baseline, but
showed a significant decreasing trend by 15 days after
cessation of treatment. [27]
Safety
In any systemic treatment, safety is of major concern, es-
pecially if the treatment is chronic. Though useful, pilo-
carpine has been found to be associated with the
following adverse effects: 4/85 (4.7%) of patients re-
ported mild headache, nausea, vomiting and sweating,
though none discontinued treatment. [25] 27/60 (45%)
of patients experienced gastrointestinal symptoms from
oral cevimeline. [28] In another study, 162/197 (82.2%)
of such patients experienced headache, increased sweat-
ing, abdominal pain or nausea, though the intensity of
these effects was mild. [22]
In patients treated with HCQ, the prevalence of serious
adverse effects was not higher than the placebo group, with
5/56 (8.9%) and 7/64 (10.9%) respectively, and these effects
were likely unrelated to the use of HCQ. [21] When partic-
ipants received 24 subcutaneous etanercept injections over
12 weeks, no cases of infection were reported, but 2
patients experienced injection-site reactions. [33] In the
TCM study, herbal treatment was associated with adverse
effects in 23/160 (15.6%) patients, compared to 8/80
(10.0%) in the placebo group. [23] Two cases of serious ad-
verse events were reported in herbal group, but they were
likely to be due to SS- associated autoimmune liver disease
rather than the herbal treatment. [23]
Conclusions
This systematic review analyzed 22 RCTs on the various
treatment options for Sjögren-related keratoconjunctivis
sicca. Although most of these studies are relatively small,
and the papers did not comply with all the Consolidated
Standards of Reporting Trials (CONSORT) require-
ments for reporting RCTs [48], there were encouraging
results for a few topical and systemic modalities. Topical
corticosteroids, oral pilocarpine and cevimeline have
been shown to improve symptoms and signs of dry eye.
Interestingly, the use of TCM herbs improved Schirmer
I results in a multi-centered, double-masked RCT.
The classification criteria for primary SS has been evolv-
ing in the past decade; the latest being the American
College of Rheumatology (ACR) and European League
Against Rheumatism (EULAR) 2016 classification [49],
which brings together the earlier ACR 2012 [50] and
American European Consensus Group (AECG) 2002 [51]
classification. This has been validated and aims to facilitate
classification of patients with early SS and those with
predominantly systemic disease [52]. While upcoming
studies will benefit from adopting 2016 classification cri-
teria, it is important to note that a number of ongoing
trials still use the 2002 AECG criteria and thus remain im-
portant in SS research. In studies on dry eyes, baseline
plasma DHEA level should be defined clearly prior to
DHEA supplementation, and lactoferrin levels should be
measured prior to lactoferrin treatment. Furthermore, the
severity of dry eye in recruited subjects should be more
clearly reported, since SS patients demonstrate a big range
of dry eye severity [53].
Longer study periods are necessary to monitor toxicity
for systemic modalities. The studies in this review were
very short. Ideally, most studies on systemic drugs
should focus on long-term outcomes [21], unless the
systemic toxicity has been assessed in previous studies.
In conclusion, this systematic review showed several
promising treatments that have clinical implications for
treatment of SS-related dry eye. Some treatment options,
eg. topical NSAIDs, should be further studied with
double-masked RCTs, larger sample sizes and stricter se-
lection criteria.
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